Board

Dr David Foster

Managing Director 

Dr Foster has 20+ years experience in life sciences representing pharmaceutical, biotherapeutic and diagnostic companies, while in private legal practice.

He served as intellectual property counsel at Medarex, a mid-sized biotherapeutics company, acquired by Bristol-Myers Squibb.

Dr Foster co-founded Roberts Foster LLP - a technology focused law firm, bionorthTx- a regional life science trade association, and multiple private biotechnology companies.

He is a board member of bionorthTx and private biotechnology companies, and is a Member of Australian Institute of Company Directors.

He holds a Ph.D. from The University of Texas Southwestern Medical Center and J.D. from Golden Gate University School of Law.

Mr Jason Carroll

Non-Executive Chair 

Mr Carroll brings over 30 years of experience in the field of life sciences and has held senior leadership roles at several multinational pharmaceutical companies including Johnson & Johnson, Janssen Pharmaceutica and iNova Pharmaceuticals.

Through his career background, Mr Carroll brings specialist expertise in both R&D and corporate strategy. His extensive experience in clinical product development includes oversight of successful market access and reimbursement programs for new drug treatments, alongside the delivery of regional M&A and business development strategies with a focus on South-East Asian markets.

Mr Carroll is a substantial shareholder in the company and also serves as CEO of Tryp Therapeutics Inc. (ASX:TYP).

Mr Chris Ntoumenopoulos

Non-Executive Director 

Mr Chris Ntoumenopoulos has more than 20 years’ financial markets experience and is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm. 
 
He was a founding director of both ResApp Health Ltd (ASX:RAP), which was acquired by Pfizer, and Race Oncology (ASX:RAC). Currently, he serves as a Non-Executive Director at TrivarX Limited (ASX:TRI) and Tryp Therapeutics (ASX: TYP).